Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation
Open Access
- 31 January 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 18 (8) , 1150-1157
Abstract
To assess persistence and adherence to rivaroxaban, dabigatran, and vitamin K antagonist (VKA) treatment in primary care patients with non-valvular atrial fibrillation (AF) newly starting anticoagulant therapy. Prescription data for oral anticoagulants were obtained from 7265 eligible patients from primary care practices across Germany. Persistence with and adherence to anticoagulation were assessed in anticoagulant-naïve patients with AF newly treated with dabigatran, rivaroxaban, or VKA during follow-up periods of at least 180 days, respectively 360 days after the prescription date. Persistence probabilities after 180 days were 66.0% for rivaroxaban, 60.3% for dabigatran, and 58.1% for VKA (P < 0.001 for rivaroxaban vs. VKA and P = 0.008 for rivaroxaban vs. dabigatran). After 360 days, persistence probabilities were 53.1, 47.3, and 25.5%, respectively (P < 0.001 for rivaroxaban and dabigatran vs. VKA). Considering the development over 360 days rivaroxaban demonstrated a better persistence compared with dabigatran (P = 0.026). Male gender and the presence of diabetes mellitus were associated with increased persistence, while renal impairment and antiplatelet drug use decreased persistence. High adherence (MPR ≥0.80) was observed in 61.4% of rivaroxaban users and in 49.5% of dabigatran users, with means of 0.76 [95% confidence interval (CI) 0.74–0.78] for rivaroxaban and 0.67 (95% CI 0.65–0.69) for dabigatran (P < 0.001). Rivaroxaban and dabigatran demonstrated better persistence than VKA at Day 360. Furthermore, rivaroxaban was associated with better persistence and adherence than dabigatran. Further studies are needed to identify factors responsible for this difference and evaluate the impact on outcomes.Keywords
Funding Information
- Bayer Pharma AG
This publication has 21 references indexed in Scilit:
- Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillationCurrent Medical Research and Opinion, 2015
- Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort studyJournal of Thrombosis and Haemostasis, 2015
- Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillationCurrent Medical Research and Opinion, 2014
- Electronically monitored dosing histories can be used to develop a medication-taking habit and manage patient adherenceExpert Review of Clinical Pharmacology, 2014
- Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants—translating clinical trial data into practiceJournal of Interventional Cardiac Electrophysiology, 2014
- Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patientsCurrent Medical Research and Opinion, 2014
- Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus WarfarinCirculation: Cardiovascular Quality and Outcomes, 2013
- Validity and representativeness of the “Disease Analyzer” patient database for use in pharmaco-epidemiological and pharmacoeconomic studiesInt. Journal of Clinical Pharmacology and Therapeutics, 2009
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- Relationship Between Adherence to Evidence-Based Pharmacotherapy and Long-term Mortality After Acute Myocardial InfarctionJAMA, 2007